Genmab upgrades guidance
The Danish biotech company has raised its financial expectations for the full year of 2022, citing continued strong sales of Darzalex and an exchange rate boost.
by astrid sturlason, translated by daniel pedersen
Danish biotech company Genmab has once again increased its ambitions for full-year 2022, a press release announced Thursday afternoon CET.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
